RecruitingPhase 3NCT07322003

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Studying Amyotrophic lateral sclerosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Prilenia
Intervention
Pridopidine(drug)
Enrollment
500 enrolled
Eligibility
18-80 years · All sexes
Timeline
20262029

Study locations (5)

Collaborators

Ferrer Internacional S.A.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07322003 on ClinicalTrials.gov

Other trials for Amyotrophic lateral sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Amyotrophic lateral sclerosis

← Back to all trials